Navigation Links
OmegaGenesis Announces Angiogenesis Application Collaboration
Date:12/15/2008

Advances Research and Product Development of Nano-Materials for Angiogenesis Applications

GILROY, Calif. and ROCHESTER, Minn., Dec. 15 /PRNewswire/ -- OmegaGenesis announced today that they have entered into a collaboration with Mayo Clinic for the discovery and validation of nano-materials used for Angiogenesis applications.

Angiogenesis plays an important role in a wide variety of medical applications ranging from tissue reactivation and healing of common wounds to controlling the growth and spread of cancer and malignancies. In cancer and malignancies, new blood vessels feed the cancer cells with oxygen and nutrients, allowing these cells to grow, invade nearby tissue, spread to other parts of the body, and form new colonies of cancer cells.

At Mayo Clinic, researchers have produced one of the rare earth materials in nano size and established non-toxicity of the material for human applications. Additionally they have shown the material induces endothelial cell growth and produces new blood vessels. Considering the current limitation of therapy to create new functional blood vessels in ischemic diseases, this finding has significant potential for clinical application.

OmegaGenesis is developing applications based on these unique characteristics of nano materials for proactive maintenance of the human body. "Our goal is to supplement natural human body management and re-enable where some natural processes have stopped or diminished. These diminished capabilities lead to dysfunction of human body. Our approach provides for early and pre-disease intervention in most cases," said Mr. Raza, CEO of OmegaGenesis.

"Our collaboration with Mayo Clinic is an example of a strategically important long-term relationship. As a result of this research and product development collaboration, fundamental research conducted by Mayo Clinic is used by OmegaGenesis in the product development process and marketplace applications," said Oostur Raza.

It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to greatly advance the treatment of primary diseases potentially affecting hundreds of millions globally.

OmegaGenesis through its collaboration with Mayo Clinic has retained exclusive license to further test Angiogenesis characteristics of these nano rods and develop products. The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.

In addition to licensing technology and patents to OmegaGenesis, Mayo Clinic and OmegaGenesis scientists will cooperate in conducting lab tests.

About OmegaGenesis

OmegaGenesis, Inc. is a venture funded bio-technology company based in Gilroy, California and Rochester, Minnesota. OmegaGenesis was founded in 2008 to bring Mayo Clinic core research and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical applications ranging from cancer and malignancies treatments to common wound healing and tissue reactivation.

The Company was founded to discover and produce suitable nano-materials to manage human body functions at a nano scale -- the cell and sub-cell level -- accelerating cellular-based biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at sub-cell level in a non-intrusive manner instead of treating the disease at the organ or tissue level.

Our mission emphasizes collaborative research in partnership with leading medical centers, rapid product design, development, and validation. OmegaGenesis collaborates with strategic academic and corporate research partners as well as international partners. For additional information, please visit OmegaGenesis's corporate Website at www.omegagenesis.com


    Media Contact:
    Heidi Chokeir, Ph.D.
    Russo Partners
    (619) 814-3512

    OmegaGenesis Contact: 
    Don Morrison
    408-483-8258


'/>"/>
SOURCE OmegaGenesis
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
2. Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury
3. Osteotech Announces Stock Repurchase Program
4. Martek Announces Fourth Quarter and FY 2008 Financial Results
5. Helix BioPharma Announces Q1 2009 Financial Results
6. Neogen Announces New Share Repurchase Program
7. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
8. Oridion Announces Significant Medical Research to be Presented at AARC Congress
9. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
10. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
11. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 More than $4.3 million was ... Medals dinner ( DHMD ). The gala was held at the ... York City and honored Alan Alda ... to health and medicine and the public understanding of science. ... 2006, the event has raised $40 million for the Laboratory,s ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the ... and a beautiful technology experience. All three tenets were on display at the 2nd ... leaders from over 40 sponsor, CRO and site organizations to discuss innovation and the ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
Breaking Biology Technology:
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
Breaking Biology News(10 mins):